An interventional study of Transitions Program in Cancer, Cancer Survivorship and Adolescent and Young Adult Cancer Survivors, sponsored by University of Kansas Medical Center. Not yet recruiting. Open to participants aged 18 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Supportive care
This is a single-arm, minimal-risk, interventional behavioral clinical trial embedding structured transition support for adolescent and young adult (AYA) survivors of pediatric cancer transitioning into adult-focused survivorship care. Aims are to improve AYA transition from pediatric to adult survivorship care and to enhance AYA access to fertility education and care.
Patient Participants will:
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 100 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →University of Kansas Medical Center is the lead sponsor of 484 studies on the registry; 113 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Undergoing active treatment for cancer or recurrence
Participants will receive: 1. A pre-transition developmental needs assessment 2. Up to 2 years of AYA nurse navigation support
Behavioral: Transitions Program
Participants will receive: 1. A pre-transition developmental needs assessment 2. Up to 2 years of AYA nurse navigation support
Primary outcome is transition success (Goal: 80% of referred)
Medical record abstraction will be used to collect detailed information on each participant's cancer history and follow-up care. This process will include extraction of key clinical data such as cancer diagnosis, dates of treatment, treatment location, and specific treatment modalities, including radiation and chemotherapy doses. Additional information on relapse history, occurrence of secondary malignancies, and adherence to COG screening recommendations will also be obtained. Data on subspecialty referrals, scheduled appointment dates, and attendance at those appointments will be recorded to assess patterns of care and follow-up.
Time frame: Medical record abstraction at baseline and annually for 3 years.
Adolescent and young adult engagement and feedback
Semi-structured interviews with AYA patients will collect qualitative feedback focused on feasibility, acceptability, and utility of the program. For AYAs who do not participate in the program, interviews will inquire about barriers or reasons for non-participation. Interviews will focus on the following core topics: overall experience with pre-transition assessment and navigation, clarity and relevance of information provided, access to recommended resources and barriers, fertility education experience and referrals, self-management and transition readiness changes, suggestions to improve the program, and preferred mode/timing of contacts.
Time frame: Assessed by structured interviews at 18 & 36 mo.
Adherence to Children's Oncology Group (COG) survivorship guidelines.
Medical record abstraction will be used to collect detailed information on each participant's cancer history and follow-up care. This process will include extraction of key clinical data such as cancer diagnosis, dates of treatment, treatment location, and specific treatment modalities, including radiation and chemotherapy doses. Additional information on relapse history, occurrence of secondary malignancies, and adherence to COG screening recommendations will also be obtained. Data on subspecialty referrals, scheduled appointment dates, and attendance at those appointments will be recorded to assess patterns of care and follow-up.
Time frame: Will be assessed by medical record abstraction at baseline, and annually for 3 years.
Demographic and diversity-related factors of representation
The Behavioral Measurement-Based Care in Psychiatry (BMCP) Diversity Dimensions Measurement Tool is a checklist assessing demographic and diversity-related factors to examine representation. After baseline, we will shorten this measure by only including demographic factors that have potential to change over time.
Time frame: Will be assessed at baseline and years 1-3.
Transition Readiness
The Transition Readiness Assessment Questionnaire (TRAQ13) is a questionnaire assessing preparedness for transition to adult healthcare.
Time frame: Will be measured at baseline and years 1-3.
Health-Related Quality of Life
National Institutes of Health (NIH) Patient Reported Outcomes Measurement Information System (PROMIS)-29+2 is a tool to measure health-related quality of life.
Time frame: Will be measured at baseline and years 1-3.
Reproductive Concerns
The Reproductive Concerns after Cancer (RCAC) scale is an instrument used to measure concerns regarding fertility and parenthood among AYA cancer survivors.
Time frame: Will be measured at baseline and years 1-3.
Economic Impact of Illness
COST-FACIT instrument quantifies the economic impact of illness from a patient's perspective (particularly in cancer care).
Time frame: Will be measured at baseline and years 1-3.
No study locations are listed for this record.
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kansas Medical Center